Powder: -20°C for 3 years | In solvent: -80°C for 1 year
1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. 4. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. 5. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 115.00 | |
5 mg | In stock | $ 279.00 | |
10 mg | In stock | $ 449.00 | |
25 mg | In stock | $ 739.00 | |
50 mg | In stock | $ 987.00 | |
100 mg | In stock | $ 1,390.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 379.00 |
Description | 1. Ginsenoside Rg5 could be a beneficial agent for the treatment of Alzheimer's disease. 2. Ginsenoside Rg5 suppresses LPS-induced nitric oxide (NO) production and proinflammatory TNF-α secretion. 3. Ginsenoside Rg5 can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. 4. Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature. 5. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E. |
Targets&IC50 | IGF-1:90 nM |
Source |
Molecular Weight | 767 |
Formula | C42H70O12 |
CAS No. | 186763-78-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mM
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ginsenoside Rg5 186763-78-0 Immunology/Inflammation Neuroscience NF-Κb Tyrosine Kinase/Adaptors NF-κB COX IGF-1R Nuclear factor-κB Inhibitor Cyclooxygenase Ginsenoside Rg 5 Nuclear factor-kappaB inhibit Ginsenoside Rg-5 inhibitor